MAP2K7 and acute myeloid leukemia: Interestingly, a recent study suggested that the new generation BMI1 inhibitor PTC-596 could be more effective in mediating apoptosis in AML when combined with the MEK inhibitor trametinib.49 Both PTC-209 and PTC-596 induce a decrease in BMI1 protein level, by interfering with post-translational mechanisms or via phosphorylation events that induce accelerated degradation29,50 respectively.